15-ketoprostaglandin-e and Peripheral-Arterial-Disease

15-ketoprostaglandin-e has been researched along with Peripheral-Arterial-Disease* in 1 studies

Other Studies

1 other study(ies) available for 15-ketoprostaglandin-e and Peripheral-Arterial-Disease

Article	Year
In Vivo Targeted Metabolomic Profiling of Prostanit, a Novel Anti-PAD NO-Donating Alprostadil-Based Drug. Molecules (Basel, Switzerland), 2020, Dec-13, Volume: 25, Issue:24 Prostanit is a novel drug developed for the treatment of peripheral arterial diseases. It consists of a prostaglandin E Topics: Alprostadil; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Chromatography, Liquid; Humans; Mass Spectrometry; Metabolic Networks and Pathways; Metabolomics; Myocytes, Smooth Muscle; Nitric Oxide; Peripheral Arterial Disease; Rabbits	2020

Article

Year

In Vivo Targeted Metabolomic Profiling of Prostanit, a Novel Anti-PAD NO-Donating Alprostadil-Based Drug.

Molecules (Basel, Switzerland), 2020, Dec-13, Volume: 25, Issue:24

Prostanit is a novel drug developed for the treatment of peripheral arterial diseases. It consists of a prostaglandin E

Topics: Alprostadil; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Chromatography, Liquid; Humans; Mass Spectrometry; Metabolic Networks and Pathways; Metabolomics; Myocytes, Smooth Muscle; Nitric Oxide; Peripheral Arterial Disease; Rabbits

2020